Evaluating multiple living kidney donor candidates simultaneously is more cost-effective than sequentially.

Markov cost cost-effectiveness analysis donation evaluation follow-up health care living kidney donor

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
12 2020
Historique:
received: 08 01 2020
revised: 13 05 2020
accepted: 04 06 2020
pubmed: 4 7 2020
medline: 26 5 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

When multiple living donor candidates come forward to donate a kidney to the same recipient, some living donor programs evaluate one candidate at a time to avoid unnecessary evaluations. Evaluating multiple candidates concurrently rather than sequentially may be cost-effective from a societal perspective if it reduces the time recipients spend on dialysis. We used a simple decision tree to estimate the cost-effectiveness of evaluating two to four candidates simultaneously rather than sequentially as potential kidney donors for the same intended recipient. Evaluating two donor candidates simultaneously cost $1,266 (CAD) more than if they were evaluated sequentially, but living donation occurred one month earlier. This translated into $6,931 in averted dialysis costs and a total cost-savings of $5,665 per intended recipient. Simultaneous evaluations also resulted in one percent more living donor transplants and overall gains in quality-of-life as recipients spent less time on dialysis. If recipients were free from dialysis at the start of donor candidate evaluations, simultaneous evaluations also reduced the rate of dialysis initiation by two percent. Benefits were also observed in the three- and four-candidate scenarios. Thus, living donor programs should consider evaluating up to four living donor candidates simultaneously when they come forward for the same recipient as health care system costs incurred are more than offset by avoided dialysis costs.

Identifiants

pubmed: 32619496
pii: S0085-2538(20)30712-2
doi: 10.1016/j.kint.2020.06.015
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1578-1588

Subventions

Organisme : CIHR
ID : GSD 140313
Pays : Canada

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Steven Habbous (S)

Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.

Lianne Barnieh (L)

Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada.

Scott Klarenbach (S)

Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Braden Manns (B)

Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; O'Brien Institute for Public Health and Libin Cardiovascular Institute, University of Calgary, Calgary Alberta, Canada.

Sisira Sarma (S)

Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada.

Mehmet A Begen (MA)

Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Ivey School of Business, Western University, London, Ontario, Canada.

Kenneth Litchfield (K)

Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (CAN-SOLVE CKD), Canada.

Krista L Lentine (KL)

Center for Abdominal Transplantation, Saint Louis University School of Medicine, St. Louis, Missouri, USA.

Sunita Singh (S)

Department of Nephrology, University Health Network, Toronto, Ontario, Canada.

Amit X Garg (AX)

Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada. Electronic address: amit.garg@lhsc.on.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH